Trending Stock News

Cognios Capital Has Cut Gilead Sciences (GILD) Position; 3 Analysts Are Bullish STERIS plc (STE) Last Week

STERIS plc (NYSE:STE) Logo

Cognios Capital Llc decreased Gilead Sciences Inc (GILD) stake by 37.12% reported in 2017Q4 SEC filing. Cognios Capital Llc sold 15,465 shares as Gilead Sciences Inc (GILD)’s stock rose 1.93%. The Cognios Capital Llc holds 26,195 shares with $1.88M value, down from 41,660 last quarter. Gilead Sciences Inc now has $87.52B valuation. The stock decreased 1.04% or $0.71 during the last trading session, reaching $67.31. About 3.89M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 21, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Among 5 analysts covering Steris (NYSE:STE), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Steris had 11 analyst reports since November 2, 2015 according to SRatingsIntel. On Wednesday, November 30 the stock rating was initiated by Goldman Sachs with “Neutral”. On Monday, October 16 the stock rating was maintained by Raymond James with “Outperform”. As per Tuesday, October 17, the company rating was maintained by KeyBanc Capital Markets. On Friday, June 3 the stock rating was upgraded by Northcoast to “Buy”. The rating was maintained by KeyBanc Capital Markets with “Buy” on Thursday, November 2. The stock of STERIS plc (NYSE:STE) earned “Buy” rating by Northcoast on Thursday, February 8. On Wednesday, January 3 the stock rating was downgraded by Raymond James to “Market Perform”. As per Thursday, February 8, the company rating was maintained by KeyBanc Capital Markets. Raymond James maintained the shares of STE in report on Wednesday, August 9 with “Outperform” rating. See STERIS plc (NYSE:STE) latest ratings:

08/02/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $103.0 Maintain
08/02/2018 Broker: Northcoast Rating: Buy New Target: $102.0 Maintain
03/01/2018 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Old Target: $100 Downgrade

More news for STERIS plc (NYSE:STE) were recently published by: Seekingalpha.com, which released: “STERIS Plc (STE) Q4 2018 Results – Earnings Call Transcript” on May 09, 2018. Globenewswire.com‘s article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture …” and published on May 03, 2018 is yet another important article.

The stock increased 1.07% or $1.11 during the last trading session, reaching $104.57. About 293,082 shares traded. STERIS plc (NYSE:STE) has risen 32.31% since May 21, 2017 and is uptrending. It has outperformed by 20.76% the S&P500.

STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support services and products for healthcare, pharmaceutical, scientific, research, industrial, and governmental clients worldwide. The company has market cap of $8.87 billion. The companyÂ’s Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories. It has a 36.83 P/E ratio. It also provides OR integration, OR and sterile processing department, workflow, patient tracking, and instrument management solutions; and cleaning chemistries and sterility assurance products.

Investors sentiment decreased to 0.17 in 2017 Q4. Its down 0.33, from 0.5 in 2017Q3. It worsened, as 4 investors sold STERIS plc shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 19,649 shares or 85.67% less from 137,131 shares in 2017Q3 were reported. Prudential Plc has 3,800 shares. Fruth Investment Management reported 0.52% in STERIS plc (NYSE:STE). Hanson Doremus Invest invested in 1,500 shares or 0.04% of the stock. Shine Investment Advisory Serv holds 0.01% in STERIS plc (NYSE:STE) or 123 shares. Alphamark Advisors invested 0.01% of its portfolio in STERIS plc (NYSE:STE).

Cognios Capital Llc increased Hanesbrands Inc Com (NYSE:HBI) stake by 21,604 shares to 94,649 valued at $1.98M in 2017Q4. It also upped Cigna Corporation Com (NYSE:CI) stake by 1,768 shares and now owns 13,508 shares. Micron Technology (NASDAQ:MU) was raised too.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Wednesday, October 28 by Maxim Group. The firm has “Buy” rating by Jefferies given on Friday, January 26. The firm earned “Outperform” rating on Wednesday, November 2 by RBC Capital Markets. The company was maintained on Wednesday, February 3 by RBC Capital Markets. The rating was downgraded by Credit Suisse on Tuesday, September 5 to “Hold”. The rating was maintained by Cowen & Co with “Buy” on Wednesday, October 18. The rating was maintained by UBS on Friday, April 29 with “Buy”. The firm has “Buy” rating given on Wednesday, November 8 by Mizuho. The stock has “Buy” rating by Berenberg on Thursday, September 22. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Market Perform” rating given on Thursday, October 19 by Leerink Swann.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.23, from 1.03 in 2017Q3. It fall, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Shelter Insurance Retirement Plan accumulated 1.35% or 42,800 shares. Windward Mngmt Ca reported 40,543 shares. Richard Bernstein Advsr Ltd Liability owns 50 shares for 0% of their portfolio. Lyons Wealth Mngmt Llc holds 1.23% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 10,504 shares. Raymond James & invested in 0.11% or 834,165 shares. Allsquare Wealth Mgmt Limited Liability Corp owns 1,200 shares or 0.07% of their US portfolio. B & T Cap Mngmt Dba Alpha Cap Mngmt holds 33,038 shares or 1.12% of its portfolio. First Eagle Invest Mgmt Ltd Liability holds 59,700 shares or 0.01% of its portfolio. California-based Ar Asset Management Incorporated has invested 0.19% in Gilead Sciences, Inc. (NASDAQ:GILD). Mycio Wealth Ltd holds 10,612 shares or 0.08% of its portfolio. Gmt Cap owns 557,400 shares. Hsbc Public Llc invested in 3.42 million shares or 0.35% of the stock. Atria Ltd Liability invested in 69,230 shares. Old Mutual Global (Uk) Ltd invested 0.01% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Cap Counsel Limited Liability Company Ny stated it has 0.41% in Gilead Sciences, Inc. (NASDAQ:GILD).

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.43 earnings per share, down 43.03% or $1.08 from last year’s $2.51 per share. GILD’s profit will be $1.86 billion for 11.77 P/E if the $1.43 EPS becomes a reality. After $1.37 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 4.38% EPS growth.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead: Where’s The Next Catalyst?” on May 18, 2018, also Bizjournals.com with their article: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” published on May 17, 2018, 247Wallst.com published: “Analysts Show More Caution Toward Gilead’s Mystical Recovery” on May 02, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “Gilead Sciences: Resist Sentiment, Stop Speculating And Invest” with publication date: May 15, 2018.

Since January 2, 2018, it had 0 buys, and 22 sales for $44.80 million activity. Cogan John Francis had sold 5,833 shares worth $440,741 on Friday, April 13. Washington Robin L had sold 5,000 shares worth $401,566 on Wednesday, February 21. 30,000 shares were sold by Alton Gregg H, worth $2.37 million. 60,000 shares were sold by WILSON GAYLE E, worth $4.68 million. Another trade for 100,000 shares valued at $8.02M was made by Meyers James R on Tuesday, January 16. $3.93 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by MARTIN JOHN C.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *